188 related articles for article (PubMed ID: 36302993)
1. Repurposing FDA-approved drugs as inhibitors of therapy-induced invadopodia activity in glioblastoma cells.
Jones D; Whitehead CA; Dinevska M; Widodo SS; Furst LM; Morokoff AP; Kaye AH; Drummond KJ; Mantamadiotis T; Stylli SS
Mol Cell Biochem; 2023 Jun; 478(6):1251-1267. PubMed ID: 36302993
[TBL] [Abstract][Full Text] [Related]
2. Enhancement of invadopodia activity in glioma cells by sublethal doses of irradiation and temozolomide.
Mao L; Whitehead CA; Paradiso L; Kaye AH; Morokoff AP; Luwor RB; Stylli SS
J Neurosurg; 2018 Sep; 129(3):598-610. PubMed ID: 29148898
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of Radiation and Temozolomide-Induced Invadopodia Activity in Glioma Cells Using FDA-Approved Drugs.
Whitehead CA; Nguyen HPT; Morokoff AP; Luwor RB; Paradiso L; Kaye AH; Mantamadiotis T; Stylli SS
Transl Oncol; 2018 Dec; 11(6):1406-1418. PubMed ID: 30219696
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of Radiation and Temozolomide-Induced Glioblastoma Invadopodia Activity Using Ion Channel Drugs.
Dinevska M; Gazibegovic N; Morokoff AP; Kaye AH; Drummond KJ; Mantamadiotis T; Stylli SS
Cancers (Basel); 2020 Oct; 12(10):. PubMed ID: 33050088
[TBL] [Abstract][Full Text] [Related]
5. Small extracellular vesicles promote invadopodia activity in glioblastoma cells in a therapy-dependent manner.
Whitehead CA; Fang H; Su H; Morokoff AP; Kaye AH; Hanssen E; Nowell CJ; Drummond KJ; Greening DW; Vella LJ; Mantamadiotis T; Stylli SS
Cell Oncol (Dordr); 2023 Aug; 46(4):909-931. PubMed ID: 37014551
[TBL] [Abstract][Full Text] [Related]
6. Invadopodia associated Thrombospondin-1 contributes to a post-therapy pro-invasive response in glioblastoma cells.
Whitehead CA; Morokoff AP; Kaye AH; Drummond KJ; Mantamadiotis T; Stylli SS
Exp Cell Res; 2023 Oct; 431(1):113743. PubMed ID: 37591452
[TBL] [Abstract][Full Text] [Related]
7. Repurposing an Antiepileptic Drug for the Treatment of Glioblastoma.
Yadav A; Alnakhli A; Vemana HP; Bhutkar S; Muth A; Dukhande VV
Pharm Res; 2022 Nov; 39(11):2871-2883. PubMed ID: 36195821
[TBL] [Abstract][Full Text] [Related]
8. Combined effects of niclosamide and temozolomide against human glioblastoma tumorspheres.
Oh HC; Shim JK; Park J; Lee JH; Choi RJ; Kim NH; Kim HS; Moon JH; Kim EH; Chang JH; Yook JI; Kang SG
J Cancer Res Clin Oncol; 2020 Nov; 146(11):2817-2828. PubMed ID: 32712753
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of TRPM7 with carvacrol suppresses glioblastoma functions in vivo.
Alanazi R; Nakatogawa H; Wang H; Ji D; Luo Z; Golbourn B; Feng ZP; Rutka JT; Sun HS
Eur J Neurosci; 2022 Mar; 55(6):1483-1491. PubMed ID: 35277895
[TBL] [Abstract][Full Text] [Related]
10. Repurposing FDA approved drugs inhibiting mitochondrial function for targeting glioma-stem like cells.
Datta S; Sears T; Cortopassi G; Woolard K; Angelastro JM
Biomed Pharmacother; 2021 Jan; 133():111058. PubMed ID: 33378970
[TBL] [Abstract][Full Text] [Related]
11. Membrane proteome analysis of glioblastoma cell invasion.
Mallawaaratchy DM; Buckland ME; McDonald KL; Li CC; Ly L; Sykes EK; Christopherson RI; Kaufman KL
J Neuropathol Exp Neurol; 2015 May; 74(5):425-41. PubMed ID: 25853691
[TBL] [Abstract][Full Text] [Related]
12. The interactome and spatial redistribution feature of Ca
Li T; Yi L; Hai L; Ma H; Tao Z; Zhang C; Abeysekera IR; Zhao K; Yang Y; Wang W; Liu B; Yu S; Tong L; Liu P; Zhu M; Ren B; Lin Y; Zhang K; Cheng C; Huang Y; Yang X
Cell Death Dis; 2018 Feb; 9(3):292. PubMed ID: 29463791
[TBL] [Abstract][Full Text] [Related]
13. Recycling drug screen repurposes hydroxyurea as a sensitizer of glioblastomas to temozolomide targeting de novo DNA synthesis, irrespective of molecular subtype.
Teng J; Hejazi S; Hiddingh L; Carvalho L; de Gooijer MC; Wakimoto H; Barazas M; Tannous M; Chi AS; Noske DP; Wesseling P; Wurdinger T; Batchelor TT; Tannous BA
Neuro Oncol; 2018 Apr; 20(5):642-654. PubMed ID: 29099956
[TBL] [Abstract][Full Text] [Related]
14. Comprehensive proteome profiling of glioblastoma-derived extracellular vesicles identifies markers for more aggressive disease.
Mallawaaratchy DM; Hallal S; Russell B; Ly L; Ebrahimkhani S; Wei H; Christopherson RI; Buckland ME; Kaufman KL
J Neurooncol; 2017 Jan; 131(2):233-244. PubMed ID: 27770278
[TBL] [Abstract][Full Text] [Related]
15. Involvement of Intracellular Cholesterol in Temozolomide-Induced Glioblastoma Cell Death.
Yamamoto Y; Sasaki N; Kumagai K; Takeuchi S; Toyooka T; Otani N; Wada K; Narita Y; Ichimura K; Namba H; Mori K; Tomiyama A
Neurol Med Chir (Tokyo); 2018 Jul; 58(7):296-302. PubMed ID: 29899179
[TBL] [Abstract][Full Text] [Related]
16. Annexin A5 promotes invasion and chemoresistance to temozolomide in glioblastoma multiforme cells.
Wu L; Yang L; Xiong Y; Guo H; Shen X; Cheng Z; Zhang Y; Gao Z; Zhu X
Tumour Biol; 2014 Dec; 35(12):12327-37. PubMed ID: 25245332
[TBL] [Abstract][Full Text] [Related]
17. Alkylaminophenol and GPR17 Agonist for Glioblastoma Therapy: A Combinational Approach for Enhanced Cell Death Activity.
Doan P; Nguyen P; Murugesan A; Candeias NR; Yli-Harja O; Kandhavelu M
Cells; 2021 Aug; 10(8):. PubMed ID: 34440745
[TBL] [Abstract][Full Text] [Related]
18. Drug Repurposing for Glioblastoma and Current Advances in Drug Delivery-A Comprehensive Review of the Literature.
Alomari S; Zhang I; Hernandez A; Kraft CY; Raj D; Kedda J; Tyler B
Biomolecules; 2021 Dec; 11(12):. PubMed ID: 34944514
[TBL] [Abstract][Full Text] [Related]
19. miR-126-3p sensitizes glioblastoma cells to temozolomide by inactivating Wnt/β-catenin signaling via targeting SOX2.
Luo W; Yan D; Song Z; Zhu X; Liu X; Li X; Zhao S
Life Sci; 2019 Jun; 226():98-106. PubMed ID: 30980849
[TBL] [Abstract][Full Text] [Related]
20. Piperlongumine-inhibited TRIM14 signaling sensitizes glioblastoma cells to temozolomide treatment.
Kuo YY; Ho KH; Shih CM; Chen PH; Liu AJ; Chen KC
Life Sci; 2022 Nov; 309():121023. PubMed ID: 36202175
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
